Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial

A Phase 3 trial showed that Gilead's Trodelvy, when combined with Merck's Keytruda, reduced the risk of progression in advanced triple-negative breast cancer by 35% as a first-line treatment, demonstrating a statistically significant improvement in progression-free survival (11.2 months vs 7.8 months with chemotherapy plus Keytruda). The results, presented at ASCO, suggest the combination could become a new standard of care for patients with PD-L1 positive tumors, a subset of triple-negative breast cancer, though overall survival data is still being collected.

Analysis

The Phase 3 trial results for Gilead Sciences' Trodelvy in combination with Merck's Keytruda represent a significant advancement in the initial treatment of advanced PD-L1 positive triple-negative breast cancer (TNBC). The combination demonstrated a 35% reduction in the risk of cancer progression compared to Keytruda plus chemotherapy, achieving a median progression-free survival (PFS) of 11.2 months versus 7.8 months for the control arm. Furthermore, the median duration of response was notably longer at 16.5 months for the Trodelvy-Keytruda arm compared to 9.2 months for the chemotherapy arm. These findings, presented at the American Society of Clinical Oncology (ASCO) meeting, strongly suggest, according to one expert, that the combination will likely become a new front-line standard of care for this patient subset, which accounts for approximately 40% of TNBC cases (TNBC itself representing about 10% of US breast cancers). The market sentiment surrounding this news is strongly positive, particularly for Gilead (GILD sentiment: 0.9) and also for Merck (MRK sentiment: 0.8), reflecting the clinical importance and potential market expansion. While overall survival data is still pending, these results significantly bolster Trodelvy's profile, an antibody-drug conjugate already approved in later-line settings. Serious side effects for the Trodelvy combination included neutropenia (43%) and diarrhea (10%), while the chemotherapy group reported neutropenia (45%), anemia (16%), and low blood platelet counts (14%).

Key Decisions for Investors

• Investors should view the positive Phase 3 results for Trodelvy in combination with Keytruda as a significant catalyst for Gilead Sciences (GILD), potentially expanding Trodelvy's approved indications to first-line PD-L1 positive triple-negative breast cancer and driving substantial revenue growth.
• For Merck (MRK), this successful trial outcome reinforces Keytruda's dominant role in oncology and its efficacy as a combination partner, likely supporting its continued strong performance in the market.
• The forthcoming overall survival data from this study is a crucial milestone to monitor, as positive results would further solidify the combination's adoption as a new standard of care and could materially impact GILD's valuation.
• Consideration should be given to Gilead's ongoing efforts to expand Trodelvy's indications, as highlighted by studies in patients who do not express PD-L1, which could further enhance its long-term value proposition if successful.